Biotronik Prepares For Next Era Of Drug-Eluting Stents
Biotronik is touting successful clinical trial results with its Orsiro sirolimus-eluting coronary stent while continuing to develop a resorbable stent.
You may also be interested in...
The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.
The company is sponsoring INFINITY SWEDEHEART, a randomized trial of its DynamX Bioadaptor, a unique metallic coronary artery implant that adapts to vessel physiology.
Acute ST-elevation myocardial infarction patients treated with Biotronik’s Orsiro biodegradable polymer sirolimus-eluting stent had a significantly lower rate of target vessel failure than patients treated with Abbott’s Xience durable polymer everolimus-eluting stent at the one-year follow-up in the BIOSTEMI trial.